ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1185

Regulatory Role of 1, 25 Dihydroxyvitamin D3 in the Pathogenesis of Autoimmune Arthritis

Siba P. Raychaudhuri1, Ananya Datta Mitra2, Anupam Mitra1, Christine Abria2 and Smriti K. Raychaudhuri2, 1Rheumatology, VA Sacramento Medical Center/UC Davis School of Medicine, Mather, CA, 2Rheumatology, VA Sacramento Medical Center, Mather, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: immune response, nutrition, psoriatic arthritis and vitamins

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fibroblast like synoviocytes (FLS) and T lymphocytes are considered as major effector cells in the pathogenesis of autoimmune arthritis (AA) such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA), due to their significant contribution in formation of pathognomonic “pannus”1,2. Several studies suggest deficiency of Vitamin D in RA and its correlation with disease severity1,3. 1,25 dihydroxyvitamin D3 (Vit D) is an active metabolite of Vitamin D3 and induces immuomodulatory effect through Vitamin D3 receptor (VDR) which is expressed on antigen presenting cells, lymphocytes, FLS. Here we are reporting the anti-proliferative and pro-apoptotic potential of Vit D in FLS and T lymphocytes of AA patients.

Methods: PBMC and FLS were isolated respectively from blood and synovial tissues of RA (n=5) and PsA (n=5) patients. CD3+ T cells were magnetically sorted from PBMC. FLS were cultured in presence or absence of growth factor (PDGF), pro-inflammatory cytokine (IL-17) and Vit D (10-6M) for 5 days. T cells were stimulated with CD3/CD28 cocktail and treated with Vit D (10-6M) for 5 days. MTT and flow cytometric (CFSE) based proliferation assays were performed. T cell apoptosis was assessed by flow cytometry using Annexin V and propidium iodide (PI). Staurosporine was used as a positive control for apoptosis assay.

Results: In MTT assay (n=5), Vit D significantly inhibited the PDGF (OD: 0.61 ± 0.06 vs. 0.23 ± 0.01, p<0.01) and IL-17 (0.55 ± 0.05 vs. 0.32 ± 0.01, p<0.01) induced proliferation of RA-FLS (Figure 1). Similar results were observed with PsA-FLS. CD3/CD28 stimulation induced significant proliferation of CD3+ T lymphocytes (17.54 ± 2.48% vs. 6.06 ± 1.13%, p<0.01) and Vit D significantly inhibited activated T lymphocytes proliferation (11.21 ± 2.28 vs. 17.54 ± 2.48%, p<0.01) (Figure 2A). We also observed that Vit D significantly induced apoptosis (Annexin V+ PI–) of T lymphocytes (26.1 ± 2.05% vs. 3.28  ± 0.17%, p<0.001) (Figure 2B).

Conclusion: This demonstrates showed that Vit D has a regulatory role in pannus formation by exerting anti-proliferative effect on two major effector cells of AA such as FLS and T lymphocytes. Moreover the pro-apoptotic effect of Vit D on activated T lymphocytes further suggests its immunomodulatory effect in AA.

 


Disclosure:

S. P. Raychaudhuri,
None;

A. Datta Mitra,
None;

A. Mitra,
None;

C. Abria,
None;

S. K. Raychaudhuri,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regulatory-role-of-1-25-dihydroxyvitamin-d3-in-the-pathogenesis-of-autoimmune-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology